60 Degrees Pharmaceuticals, Inc.
NasdaqCM SXTP
60 Degrees Pharmaceuticals, Inc. Receivables for the quarter ending September 30, 2024: USD 323.82 K
60 Degrees Pharmaceuticals, Inc. Receivables is USD 323.82 K for the quarter ending September 30, 2024, a 134.64% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.
-
60 Degrees Pharmaceuticals, Inc. Receivables for the quarter ending September 30, 2023 was USD 138.01 K, a -29.24% change year over year.
-
60 Degrees Pharmaceuticals, Inc. Receivables for the quarter ending September 30, 2022 was USD 195.04 K.
Key data
| Date | Receivables | Inventory | Goodwill | Total Assets |
|---|
Market news
Loading...
NasdaqCM: SXTP
| CEO | Dr. Geoffrey Stuart Dow |
| IPO Date | July 12, 2023 |
| Location | United States |
| Headquarters | 1025 Connecticut Avenue NW |
| Employees | 3 |
| Sector | Health Care |
| Industries | |
Description
60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email